109 related articles for article (PubMed ID: 6311971)
1. Inhibition by acyclovir of herpes simplex virus type 2 morphologically transformed cell growth in tissue culture and tumor-bearing animals.
Kucera LS; Furman PA; Elion GB
J Med Virol; 1983; 12(2):119-27. PubMed ID: 6311971
[TBL] [Abstract][Full Text] [Related]
2. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
Saijo M; Suzutani T; Yoshida I
Tohoku J Exp Med; 1992 May; 167(1):57-68. PubMed ID: 1333651
[TBL] [Abstract][Full Text] [Related]
3. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing.
Rubsam LZ; Davidson BL; Shewach DS
Cancer Res; 1998 Sep; 58(17):3873-82. PubMed ID: 9731497
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus.
Field HJ; Darby G; Wildy P
J Gen Virol; 1980 Jul; 49(1):115-24. PubMed ID: 6252285
[TBL] [Abstract][Full Text] [Related]
5. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.
Darby G; Field HJ; Salisbury SA
Nature; 1981 Jan; 289(5793):81-3. PubMed ID: 6256650
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of plaque formation of herpes simplex virus (HSV) and varicella-zoster virus (VZV) by subinhibitory dose of acyclovir (ACV).
Shiraki K; Miyaki C; Namazue J; Yamanishi K; Takahashi M
Acta Virol; 1989 Dec; 33(6):565-8. PubMed ID: 2576598
[TBL] [Abstract][Full Text] [Related]
7. Cytopathogenicity, drug susceptibility, and thymidine kinase activity of a retinovirulent herpes simplex virus type 2.
Langford MP; Colacino JM; Kaiwar R; Mahjoub SB; Ganley JP
J Med Virol; 1990 Aug; 31(4):301-5. PubMed ID: 2176674
[TBL] [Abstract][Full Text] [Related]
8. Acyclovir resistance in herpes simplex virus type 1: biochemical and functional studies on the thymidine kinase of the highly resistant R100 strain.
Palú G; Bevilacqua F; Biasolo MA; Parolin C; Tognon M; Romanelli MG; Meloni GA
Virus Res; 1989 Aug; 13(4):303-18. PubMed ID: 2554611
[TBL] [Abstract][Full Text] [Related]
9. Effect of acyclovir and presence of cellular and viral thymidine kinase activity in herpes simplex virus infected cells. Brief report.
Harmenberg J; Källander CF; Gronowitz JS
Arch Virol; 1982; 74(2-3):219-25. PubMed ID: 6299236
[TBL] [Abstract][Full Text] [Related]
10. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir.
Valerie K; Brust D; Farnsworth J; Amir C; Taher MM; Hershey C; Feden J
Cancer Gene Ther; 2000 Jun; 7(6):879-84. PubMed ID: 10880018
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient.
Christophers J; Sutton RN
J Antimicrob Chemother; 1987 Sep; 20(3):389-98. PubMed ID: 2824424
[TBL] [Abstract][Full Text] [Related]
12. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.
Larder BA; Darby G
Virology; 1985 Oct; 146(2):262-71. PubMed ID: 2996220
[TBL] [Abstract][Full Text] [Related]
13. Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
Schnipper LE; Crumpacker CS; Marlowe SI; Kowalsky P; Hershey BJ; Levin MJ
Am J Med; 1982 Jul; 73(1A):387-92. PubMed ID: 6285729
[TBL] [Abstract][Full Text] [Related]
14. Uptake of [125I]iododeoxycytidine by cells infected with herpes simplex virus: a rapid screening test for resistance to acyclovir.
Van Dyke RB; Connor JD
J Infect Dis; 1985 Dec; 152(6):1206-11. PubMed ID: 2999258
[TBL] [Abstract][Full Text] [Related]
15. The biochemistry and mechanism of action of acyclovir.
Elion GB
J Antimicrob Chemother; 1983 Sep; 12 Suppl B():9-17. PubMed ID: 6313600
[TBL] [Abstract][Full Text] [Related]
16. Preliminary characterization of a mutant of herpes simplex virus type 1 selected for acycloguanosine resistance in vitro.
Palú G; Summers WP; Valisena S; Tognon M
J Med Virol; 1988 Mar; 24(3):251-62. PubMed ID: 2835423
[TBL] [Abstract][Full Text] [Related]
17. Establishment of mutant murine mammary carcinoma FM3A cell strains transformed with the herpes simplex virus type 2 thymidine kinase gene.
Shimizu K; Ren L; Ayusawa D; Seno T; Balzarini J; De Clercq E
Cell Struct Funct; 1986 Sep; 11(3):295-301. PubMed ID: 3021345
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells.
Darby G; Larder BA; Bastow KF; Field HJ
J Gen Virol; 1980 Jun; 48(Pt 2):451-4. PubMed ID: 6249891
[TBL] [Abstract][Full Text] [Related]
19. Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum® assay.
Sauerbrei A; Vödisch S; Bohn K; Schacke M; Gronowitz S
J Virol Methods; 2013 Mar; 188(1-2):70-2. PubMed ID: 23246510
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
